Genfleet Therapeutics (Shanghai), Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-08-23
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genfleet.com
Clinical Trials
8
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:6
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (75.0%)Phase 2
2 (25.0%)A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT07026916
A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia
Phase 1
Recruiting
- Conditions
- Cancer Cachexia
- Interventions
- Drug: GFS202A injection
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06898255
- Locations
- 🇨🇳
Sun-Yat Sen university cancer center, Guangzhou, Guangdong, China
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 390
- Registration Number
- NCT06500676
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT06375733
- Locations
- 🇨🇳
Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Nanning, China
🇨🇳Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, Zhengzhou, China
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05934513
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
- Prev
- 1
- 2
- Next
News
No news found